1 / 1

VPRIV(Velaglucerase Alfa for Injection)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

POWDER

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

MOUNJARO (tirzepatide) is a novel dual GIP and GLP-1 receptor agonist used for the management of type 2 diabetes mellitus. As a once-weekly injectable, MOUNJARO is designed to provide significant improvements in glycemic control, reduce HbA1c levels, and promote weight loss, which are key concerns for individuals with type 2 diabetes. Its unique mechanism of action targets both insulin secretion and glucagon suppression, contributing to effective blood glucose regulation.

In clinical trials, MOUNJARO demonstrated superior efficacy over other antidiabetic therapies, making it an important addition to the treatment options available for type 2 diabetes. Administered as a subcutaneous injection, MOUNJARO allows for ease of use and flexibility for patients, with dose escalation tailored to the individual’s glycemic needs.

Generic name

VPRIV(Velaglucerase Alfa for Injection)

English name

Velaglucerase Alfa for Injection

Alternative Names

VPRIV

Drug prices

Indications

Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease

Therapeutic Target

Hydrolyzes accumulated glucocerebroside in lysosomes of macrophages, reducing lipid storage in Gaucher cells.

Active Ingredients

Velaglucerase alfa (recombinant human beta-glucocerebrosidase).

Dosage form

POWDER

specifications

Single-dose vials: 400 units/vial.

Description

Molecular characteristics: Glycoprotein (497 amino acids; ~63 kDa) with high mannose-type N-linked glycan chains.

Mechanism: Catalyzes hydrolysis of glucocerebroside to glucose and ceramide.

Reconstitution: Each vial contains 400 units of velaglucerase alfa, citric acid monohydrate, polysorbate 20, sodium citrate dihydrate, and sucrose.

Reconstituted solution: 100 units/mL (pH ~6.0) after adding 4.3 mL Sterile Water for Injection.

Dosage and Administration

Dosing

Naïve patients: 60 Units/kg every other week (60-minute IV infusion).

Switching from imiglucerase: Administer equivalent dose to prior imiglucerase regimen, starting 2 weeks after last imiglucerase dose.

Reconstitution and Administration

Reconstitute with 4.3 mL Sterile Water for Injection.

Dilute in 100 mL 0.9% Sodium Chloride Injection.

Infuse via in-line 0.2 or 0.22 µm filter over 60 minutes.

Storage: Use immediately or refrigerate (2–8°C) for ≤24 hours; do not freeze

CATEGORY NAVIGATION